Researchers finalizing study to eliminate Alzheimer’s disease (ALZ) at earliest stage.
Online PR News – 13-November-2015 – Ridgefield, CT – MMT Neurotech announced their collaboration with the Cognitive and Research Center of New Jersey, a major provider of neuroscience and neurocognitive research and support in the northeast. The center supports patients with clinical services and assists with neurologic pharmaceutical clinical trials. The center will be providing memory and cognitive evaluation of patients at high risk for Alzheimer’s Disease in preparation for their possible treatment in MMT Neurotech’s new study for the early identification and preventive treatment of pre-clinical Alzheimer's Disease (ALZ). This new clinical trial protocol will verify two recent and very critical concepts in ALZ Clinical Research: that the development of Alzheimer’s Disease can be predicted in individuals who do not have current memory impairment and that using preventative treatment in these individuals at risk for ALZ can stop development of the disease.
Dr. Donald Marks, founder and Chief Science Officer, explains: “With MMT’s proprietary neuroimaging approaches to identify early brain changes, it is possible to predict the future development of ALZ at least 18 to 48 months before any symptoms of memory loss have developed. We will then initiate early, preventative treatment for these otherwise normal individuals at high risk of developing ALZ.”
Early treatment may be the key to preventing progression to symptomatic Alzheimer ’s disease. The Cognitive and Research Center of New Jersey will be one of the centers to provide screening of interested and at risk patients. They will also provide follow up evaluation to document that the treatment approach is working.
MMT NeuroTech is collaborating with a non-profit health care group and an expanded group of physicians experienced in diagnosing and treating ALZ along with their experienced fMRI centers in the conduct of this protocol.
“The patients who are at risk will include those who self-identify as having more memory problems than their peers, those with a special gene type called APOE4, and those with first degree relatives with Alzheimer’s such as parents or siblings”, indicates Dr. Steven Levy, CEO of MMT Neurotech. “The goal is show that early treatment can stop progression and thereby help people maintain their mental acuity and enjoy a happy and productive maturity.”
The number of ALZ patients is expected to grow 40% by 2025 with the total Americans with the disease projected to increase to 13.8 million, so this is a critical effort. MMT posits that prevention will be a vital tool in reducing the impact of ALZ.
“With our newest protocols, MMT believes it should be possible to prevent or slow the development of the disease “, indicated Dr. Marks. “Our goal is to move patient attitudes about Alzheimer’s Disease from - I don’t want to know - to - tell me if I’m at risk so I can maintain my memory”.
MMT Neurotech is commercializing neuroimaging for a number of clinical conditions including objectively documenting the presence of pain for personal injury cases and disability claims, establishing fibromyalgia, identifying depression and suicidal ideation, monitoring for deception or lie detection with greater than 90% accuracy, real-time memory recordings, as well as providing the earliest possible diagnosis and therefore treatment of Autism Spectrum Disorders and pre-Alzheimer’s disease.
For more information about MMT.Neurotech and this study contact: Steven Levy MD or Donald H. Marks MD PhD MMT NeuroTech is a New Jersey / Connecticut neurotechnology company which commercializes disruptive neuroimaging technologies to image thought.